Syntis Bio Launches, Focusing On Oral Obesity Drugs And Rare Diseases

The company formed around technology from the labs of MIT’s Robert Langer and Giovanni Traverso and already has a lead asset in the clinic.

intestine
Syntis bio is developing drugs for obesity • Source: Shutterstock

Syntis Bio, Inc. is a new company based in Boston that is joining the rush to develop oral drugs for obesity. The company believes it has an original approach – harnessing the small intestine’s biology for digestion and drug absorption – that will separate it from the pack, however.

Key Takeaways

  • Syntis Bio is a new company focused on the development of oral drugs for obesity focused on the small intestine.

The company made its public debut on 11 June, announcing its launch as a clinical-stage company. Syntis Bio was originally...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Start-Ups & SMEs

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.